Sekisui Chemical Co., Ltd.

DUBLIN--( BUSINESS WIRE )--The "Clinical Laboratory Molecular Diagnostics for Infectious Disease Market: Forecasts by Application by Place and by Country, with Market Analysis & Executive Guides" report has been added to ResearchAndMarkets.com's offering. The report has hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help sharpen your pricing along with the most frequently used and billed tests. Again, assistance in using the information is normally provided without additional charges. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report. The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for further growth. A market that just keeps on growing but is becoming more complex and segmented. Find out what's happening in this informative report. Find out about the impact of multiplex assays which threaten to change diagnosis and treatment forever. Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication. This research makes you the expert in your organization. The report includes five year market forecasts. The section on the Clinical Laboratory Market Segments and Industry Structure provides an analysis of the laboratory market, detailing traditional segmentation and focusing on specific areas like syndromic testing. It explores how different types of labs, including hospital labs, central labs, and physician office labs (POLs), segment their services based on testing needs. The industry structure section discusses the distribution of testing among hospitals, the economies of scale achieved by larger lab networks, and the competition between hospital-based labs and centralized laboratories. It also highlights the role of physician offices and the growing relevance of Point-of-Care Testing (POCT), reflecting the shifting dynamics in where and how diagnostic testing is conducted. This summary encapsulates the key market dynamics and structural elements of the clinical laboratory industry. Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations. Trends like Multiplex testing Pathogen evolution and pandemics Biotechnology advances in genetics Climate change Globalization The rise of rapid testing Key Topics Covered: 1 Market Guides 1.1 Situation Analysis 2 Introduction and Market Definition 2.1 Market Definition 2.2 Methodology 2.3 Perspective: Healthcare and the IVD Industry 2.3.1 Global Healthcare Spending 2.3.2 Spending on Diagnostics 2.3.3 Important Role of Insurance for Diagnostics 2.4 The Nature of the IVD Product 2.4.1 Features Overview 2.4.2 The Misunderstood Feature 2.4.3 Regulation 2.4.4 The Newest Feature 2.4.5 The Oldest Feature 2.4.6 All About Scope 2.4.7 Why Turnaround is Becoming More Important 2.4.8 The Role of Trust 2.5 The IVD Product of the Future 3 Infectious Diseases - Guide to the Pathogens 3.1 Infectious Disease Pathogens - The Big Picture 3.1.1 Viruses 3.1.2 Bacteria 3.1.3 Fungi 3.1.4 Parasites 3.1.5 Prions 3.1.6 Virulence 3.1.7 Transmission 3.2 The Coronavirus 3.2.1 Severe acute respiratory syndrome (SARS) 3.2.2 Middle East respiratory syndrome (MERS) 3.2.3 COVID-19. The SARS CoV 2 Virus. 4 Industry Overview 4.1 Players in a Dynamic Market 4.1.1 Academic Research Lab 4.1.2 Diagnostic Test Developer 4.1.3 Instrumentation Supplier 4.1.4 Chemical/Reagent Supplier 4.1.5 Pathology Supplier 4.1.6 Independent Clinical Laboratory 4.1.7 Public National/regional Laboratory 4.1.8 Hospital Laboratory 4.1.9 Physicians Office Lab (POLS) 4.1.10 Audit Body 4.1.11 Certification Body 4.2 The Clinical Laboratory Market Segments 4.2.1 Traditional Market Segmentation 4.2.2 Laboratory Focus and Segmentation 4.2.3 Segmenting the Syndromic Testing Market 4.3 Industry Structure 4.3.1 Hospital Testing Share 4.3.2 Economies of Scale 4.3.3 Hospital vs. Central Lab 4.3.4 Physician Office Labs 4.3.5 Physicians and POCT 5 Market Trends 5.1 Factors Driving Growth 5.1.1 The Nucleic Acid Impact 5.1.2 Population Dynamics 5.1.3 The Developing World 5.1.4 Decentralization 5.1.5 Self Testing 5.1.6 The Need for Speed 5.2 Factors Limiting Growth 5.2.1 Costs and Experience Curve Effects 5.2.2 The Role of ID Prevalence 5.2.3 Wellness 5.2.4 The Impact of Living Standards 5.3 Instrumentation, Automation and Diagnostic Trends 5.3.1 Traditional Automation and Centralization 5.3.2 The New Automation, Decentralization and Point Of Care 5.3.3 Instruments Key to Market Share 5.3.4 Bioinformatics Plays a Role 5.3.5 PCR Takes Command 5.3.6 Next Generation Sequencing Fuels a Revolution 5.3.7 NGS Impact on Pricing 5.3.8 Whole Genome Sequencing, A Brave New World 5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 6 Clinical Laboratory MDx Infectious Disease Recent Developments 6.1 Recent Developments - Importance and How to Use This Section 6.1.1 Importance of These Developments 6.1.2 How to Use This Section 6.2 Roche Respiratory Panel Receives FDA EUA 6.3 Genetic Signatures Gets Approval for GI Parasite Panel 6.4 Diasorin Expands Respiratory Panel 6.5 BioMerieux Outlines MDx-Driven Growth 6.6 T2 Biosystems Gets Extended T2Bacteria Panel 6.7 Diasorin Aims to Deliver Updated Instruments, New Assays 6.8 Oxford Nanopore Nabs Investment From BioMerieux 6.9 Day Zero Diagnostics Closes Financing Round 6.10 Spindiag Seeks Investors for Rapid PCR System 6.11 Sorrento Therapeutics Nabs Contract for Dx Platform 6.12 Kephera Planning Menu of Infectious Disease Tests 6.13 Oxford Nanopore and BioMerieux to Develop IDDx 6.14 SD Biosensor Eyes Global Expansion 6.15 Selux Dx Next Gen Phenotyping Gets FDA Clearance 6.16 Takara Developing High-Throughput Multiplex Panels 6.17 BioGX Debuts New Point-of-Care Molecular Testing System 6.18 Nanopath MDx Platform Providing 15-Minute Results 6.19 ProtonDx Commercializing Rapid MDx Instrument 6.20 Siemens Healthineers to Develop Next-Gen, High-Throughput MDx Platform 6.21 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays 6.22 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS 6.23 Accelerate Diagnostics Anticipates Growth 6.24 Growth of Decentralized Testing Expected to Continue 6.25 Lumos Diagnostics Expanding Test Portfolio 6.26 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens 6.27 CareDx, IDbyDNA Develop Infectious Disease Dx for Transplant Patients 7 Key Companies 7.1 Abbott Laboratories 7.2 Agilent 7.3 Altona Diagnostics 7.4 Anitoa 7.5 Autonomous Medical Devices 7.6 Beckman Coulter Diagnostics (Danaher) 7.7 Becton, Dickinson and Company 7.8 BioGX 7.9 Biomatik 7.10 bioMerieux Diagnostics 7.11 Bio-Rad Laboratories, Inc 7.12 Cepheid (Danaher) 7.13 Diasorin S.p.A. 7.14 DNAe 7.15 Flow Health 7.16 Global Access Diagnostics 7.17 Great Basin Scientific, Inc 7.18 Hologic 7.19 Novacyt 7.20 Novus Diagnostics 7.21 Oncimmune 7.22 One Codex 7.23 OraSure Technologies 7.24 Proof Diagnostics 7.25 Qiagen 7.26 QuidelOrtho 7.27 R-Biopharm AG 7.28 Response Biomedical 7.29 Revvity 7.30 Roche Diagnostics 7.31 Siemens Healthineers 7.32 Thermo Fisher Scientific 7.33 Vela Diagnostics 7.34 Veredus Laboratories 7.35 YD Diagnostics 7.36 Zhejiang Orient Gene Biotech 8 The Global Market for Clinical Laboratory MDx Infectious Disease 8.1 Global Market Overview by Country 8.2 Global Market by Application - Overview 8.3 Global Market by Place - Overview 9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application 9.1 Respiratory 9.2 Blood Borne Virus 9.3 Transplant 9.4 Hospital Acquired Infections 9.5 Reproductive Health 9.6 C19 Singleplex 9.7 Meningitis 9.8 Gastrointestinal 9.9 Tropical 10 Global Clinical Laboratory MDx Infectious Disease Markets - By Place 10.1 Hospital Lab 10.2 Outpatient Lab 10.3 Point of Care 10.4 Other Place 11 Appendices 11.1 Growth of Approved IVD Test Menu 11.2 Growth of Approved Average IVD Test Fee 11.3 The Most Used IVD Assays 11.4 The Highest Grossing Assays 11.5 Laboratory Fees Schedule For more information about this report visit https://www.researchandmarkets.com/r/fte25m About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

SEKISUI Diagnostics' microbial CDMO business has completed construction of its EUR 15.7 million (USD 20.7 million) cGMP capacity expansion at its UK site for clinical-grade drug substance manufacturing. Following appropriate licensure, this expansion will enable manufacturing capabilities for common drug types including enzymes, proteins and antibody fragment therapies, as well as plasmids and enzymes for cutting-edge gene therapy manufacture. BioProduction by SEKISUI is SEKISUI Diagnostics' contract service offering as a fermentation-focused CDMO with expertise in proteins and downstream purification. Their microbial process development and production experience helps smooth technical transfer and process scale-up. The new Grade C microbial fermentation and purification suites will accommodate production scales up to 1,000L. "This investment supports the vision and mission of SEKISUI Diagnostics and the broader SEKISUI Medical Group by enabling the continued growth of our share of the biologics CDMO market," said Robert Schruender, President & CEO of SEKISUI Diagnostics. "We look forward to working with biopharma companies seeking an experienced partner at a time when demand is outstripping manufacturing capacity," added Schruender. Louise Digby, Vice President, Enzymes & BioProduction at SEKISUI Diagnostics added, "Over many years we have honed our technical and operational competency and expertise in enzyme production and microbial fermentation to serve our partners globally. This cGMP expansion enables us to support a broader customer base and expand our offering to existing customers."

Growth of UK facility will enable clinical-grade manufacturing of drug substances for range of biopharmaceutical products BURLINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- SEKISUI Diagnostics' microbial CDMO business announces it has completed construction of its £15.7 million ($20.7 million) cGMP capacity expansion at its UK site for clinical-grade drug substance manufacturing. Following appropriate licensure, this expansion will enable manufacturing capabilities for common drug types including enzymes, proteins and antibody fragment therapies, as well as plasmids and enzymes for cutting-edge gene therapy manufacture. Continue Reading Fermentation Gantry BioProduction by SEKISUI is SEKISUI Diagnostics' contract service offering as a fermentation-focused CDMO with expertise in proteins and downstream purification. Their microbial process development and production experience helps smooth technical transfer and process scale-up. The new Grade C microbial fermentation and purification suites will accommodate production scales up to 1,000L. "This investment supports the vision and mission of SEKISUI Diagnostics and the broader SEKISUI Medical Group by enabling the continued growth of our share of the biologics CDMO market," said Robert Schruender, President & CEO of SEKISUI Diagnostics. "We look forward to working with biopharma companies seeking an experienced partner at a time when demand is outstripping manufacturing capacity." Louise Digby, Vice President, Enzymes & BioProduction at SEKISUI Diagnostics added: "Over many years we have honed our technical and operational competency and expertise in enzyme production and microbial fermentation to serve our partners globally. This cGMP expansion enables us to support a broader customer base and expand our offering to existing customers." About SEKISUI Diagnostics We are part of SEKISUI Medical Group with over 40 years of experience supplying innovative medical diagnostics globally to physicians, hospitals, laboratories and alternate testing locations. Our product lines include clinical chemistry reagents, point-of-care tests, pre-analytic systems as well as enzymes, specialty biochemicals and the microbial CDMO business, BioProduction by SEKISUI. About SEKISUI Medical Group SEKISUI Medical Group is a diverse, global network consisting of a diagnostics business and pharmaceutical sciences business which spans drug development services and manufacturing, including active pharmaceutical ingredients and pharmaceutical intermediates, amino acids, as well as a wide range of enzymes for use in diagnostics, and biopharmaceutical contract manufacturing and more. SOURCE SEKISUI DIAGNOSTICS, LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED